Molecular-biological tumor profiling for drug treatment selection in patients with advanced and refractory carcinoma

Medical University of Graz0 sites64 target enrollmentMarch 19, 2015

ConditionsPatients with locally advanced and/ or metastasized carcinoma for whom no further evidence-based drug treatment is established.A progression of the tumor is confirmed due to the last evidence-based drug therapy. Due to circulating tumor-DNA (ctDNA) in a blood sample and/or tissue sample of metastasis, a molecular-biologic tumor profiling is performed and an adapted tumor-specific drug therapy is selected.Therapeutic area: Diseases [C] - Cancer [C04]

DrugsZytiga Kadcyla Giotrif Arimidex Trisenox Erwinase Inlyta Vidaza Levact Avastin

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Patients with locally advanced and/ or metastasized carcinoma for whom no further evidence-based drug treatment is established.A progression of the tumor is confirmed due to the last evidence-based drug therapy. Due to circulating tumor-DNA (ctDNA) in a blood sample and/or tissue sample of metastasis, a molecular-biologic tumor profiling is performed and an adapted tumor-specific drug therapy is selected.
Sponsor: Medical University of Graz
Enrollment: 64
Status: Active, not recruiting
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

March 19, 2015

End Date

TBD

Last Updated

7 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

Medical University of Graz

Eligibility Criteria

Inclusion Criteria

•1\. Male/ female patients with locally advanced and/ or metastasized carcinoma for whom no further evidence\-based drug therapy is established.
•2\. Diagnosis of unresectable locally advanced and/or metastatic carcinoma with histologically confirmed disease
•3\. Confirmed progression after evidence\-based drug therapy and no option for further evidence\-based drug therapy (at least one phase III study) in this indication
•4\. Age \>18 years \- \=85
•5\. Life expectancy of at least 12 weeks
•6\. Measureable disease according to the revised RECIST criteria version 1\.1\. (Eisenhauer, E.A., et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1\.1\). Eur J Cancer, 2009\. 45(2\): p. 228\-47\.) Das ist die Referenz 3
•7\. ECOG score 0\-2 (Appendix A)
•8\. Adequate bone marrow, liver and kidney function:
•laboratory cut\-off levels according to the registration of registered drugs (will be checked again before treatment start)
•9\. No anti\-tumor therapy including radiotherapy in the past two weeks.

Exclusion Criteria

•1\. Significant comorbidity which is expected to affect patient's prognosis or ability to receive therapy:
•a. History of significant cardiovascular disease unless the disease is well controlled. Significant cardiac disease includes second/ third degree heart block; significant ischemic heart disease; poorly controlled hypertension; congestive heart failure of the New York Heart Association (NYHA) class II or worse (slight limitation of physical activity; comfortable at rest but ordinary activity results in fatigue, palpitation or dyspnea).
•b. History of arrhythmia that is symptomatic or requires treatment. Patients with atrial fibrillation or flutter controlled by medication are not excluded from participation in the trial.
•c. Active infection or any serious underlying medical condition that would impair the ability of the patient to receive protocol therapy.
•d. History of any psychiatric condition that might impair the patient's ability to understand or comply with the requirements of the study or to provide consent.
•e. Hypersensitivity with anaphylactic reaction to humanized monoclonal antibodies or any of the applied drugs
•2\. Untreated CNS metastases. Patients with treated brain metastases are eligible if they are clinically stable with regard to neurologic function, off steroids after cranial irradiation (whole brain radiation therapy, focal radiation therapy, and stereotactic radiosurgery) ending at least 2 weeks prior to treatment start, or after surgical resection performed at least 28 days prior to treatment start.
•3\. Previously diagnosed malignancies except for adequately treated non\-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease free for at least 5 years.
•4\. Pregnant or breast feeding